Item 2.02. Results of Operations and Financial Condition.

The information in this Current Report (including Exhibits 99.1 and 99.2) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibits 99.1 and 99.2) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On January 9, 2023, Theravance Biopharma, Inc. (the "Company") issued a press release providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Additionally, members of the Company management team will be conducting one-on-one meetings with analysts and investors in San Francisco, CA from January 9-12, 2023, using a slide presentation which includes an update regarding the Company's anticipated operating expense range for the year ended December 31, 2022 and is being furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.



   99.1     Press Release dated January 9, 2023




   99.2     Slide deck entitled Theravance Biopharma Investor Presentation

104 Cover Page Interactive Data File (cover page XBRL tags embedded within the

Inline XBRL document)

© Edgar Online, source Glimpses